Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma

Rachel L Mynott; Craig T Wallington-Beddoe

doi:10.1021/acsptsci.1c00074

Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma

Rachel L Mynott, Craig T Wallington-Beddoe

College of Medicine and Public Health

Research output: Contribution to journal › Article › peer-review

Abstract

Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.

Original language	English
Number of pages	16
Journal	ACS Pharmacology and Translational Science
Early online date	15 Apr 2021
DOIs	https://doi.org/10.1021/acsptsci.1c00074
Publication status	E-pub ahead of print - 15 Apr 2021

Keywords

Multiple myeloma
Drug resistance
ABC transporters
SLC transporters
multiple myeloma
drug resistance

Access to Document

10.1021/acsptsci.1c00074Licence: In Copyright

Fingerprint Dive into the research topics of 'Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma'. Together they form a unique fingerprint.

Cite this

@article{f7ca747d053f46aea487954beac43b52,

title = "Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma",

abstract = "Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.",

keywords = "Multiple myeloma, Drug resistance, ABC transporters, SLC transporters, multiple myeloma, drug resistance",

author = "Mynott, {Rachel L} and Wallington-Beddoe, {Craig T}",

year = "2021",

month = apr,

day = "15",

doi = "10.1021/acsptsci.1c00074",

language = "English",

journal = "ACS Pharmacology and Translational Science",

issn = "2575-9108",

}

TY - JOUR

T1 - Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma

AU - Mynott, Rachel L

AU - Wallington-Beddoe, Craig T

PY - 2021/4/15

Y1 - 2021/4/15

N2 - Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.

AB - Multiple myeloma remains an incurable malignancy of plasma cells. Novel therapies, notably proteasome inhibitors and immunomodulatory drugs, have improved the survival of multiple myeloma patients; however, patients either present with, or develop resistance to, these therapies. Resistance to traditional chemotherapeutic agents can be caused by cellular drug efflux via adenosine triphosphate (ATP)-binding cassette (ABC) transporters, but it is still not clear whether these transporters mediate resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma. Solute carrier (SLC) transporters also play a role in cancer drug resistance due to changes in cell homeostasis caused by their abnormal expression and changes in the solutes they transport. In this review, we evaluate resistance to novel therapies used to treat multiple myeloma, as mediated by drug and solute transporters.

KW - Multiple myeloma

KW - Drug resistance

KW - ABC transporters

KW - SLC transporters

KW - multiple myeloma

KW - drug resistance

UR - http://www.scopus.com/inward/record.url?scp=85105748964&partnerID=8YFLogxK

U2 - 10.1021/acsptsci.1c00074

DO - 10.1021/acsptsci.1c00074

M3 - Article

JO - ACS Pharmacology and Translational Science

JF - ACS Pharmacology and Translational Science

SN - 2575-9108

ER -

Drug and Solute Transporters in Mediating Resistance to Novel Therapeutics in Multiple Myeloma

Abstract

Keywords

Access to Document

Other files and links

Cite this